The Antimonopoly Committee of Ukraine has initiated a review of the case concerning five leading pharmacy chains in the capital, which encompass 155 business entities.
This is reported by Kyiv24
Suspicion of Abuse of Market Power
According to the Antimonopoly Committee, these chains control 64% of the total retail turnover of pharmaceutical products and own 42% of all pharmacy outlets — totaling 7,742 commercial entities. The combined market share of these chains is significant, allowing them to potentially influence the conditions of goods circulation and pricing.
The agency emphasizes that there are signs of violations of legislation regarding the protection of economic competition, particularly the abuse of market power.
Restrictions on Domestic Producers’ Goods
Since February 2025, the Antimonopoly Committee has observed a decrease in the sales volumes of pharmaceutical products from three Ukrainian manufacturers. This is occurring due to restrictions on the availability of their products in the five largest pharmacy chains, even though the demand for these medications has remained stable and has not shown a tendency to decline.
The Committee believes that the decrease in the purchase levels of these medications is directly related to their limited presence on pharmacy shelves, rather than a change in consumer demand.
The Committee notes that these were coordinated actions by the pharmacy groups. This violation carries responsibility as stipulated by law.